WEBULL
News
ACHFF
0.880
-1.90%
-0.017
Arch granted ethics approval for St. Michaels participation in Phase II trial
TipRanks · 12/16 12:45
Arch Biopartners Wins Ethics Approval for Phase II Cardiac Surgery-Associated AKI Trial at St. Michael’s Hospital
Reuters · 12/16 12:40
Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide
Barchart · 12/16 06:40
Arch Biopartners Raises $600,000 in Private Placement of Common Shares
Reuters · 11/19 21:34
ARCH BIOPARTNERS CLOSES NON-BROKERED PRIVATE PLACEMENT
Reuters · 11/19 21:27
Arch biopartners launches non-brokered private placement
Seeking Alpha · 11/10 14:16
Arch Biopartners Announces $500,000 Private Placement of Common Shares
Reuters · 11/10 13:20
ARCH BIOPARTNERS ARRANGES NON-BROKERED PRIVATE PLACEMENT
Reuters · 11/10 13:10
Arch Biopartners Arranges Non-Brokered Private Placement
Barchart · 11/10 07:10
ARCH BIOPARTNERS EXPANDS PHASE II CARDIAC SURGERY-ASSOCIATED AKI TRIAL TO INCLUDE ROYAL COLUMBIAN HOSPITAL IN BRITISH COLUMBIA
Reuters · 11/05 13:30
Weekly Report: what happened at ACHFF last week (0908-0912)?
Weekly Report · 09/15 10:35
Weekly Report: what happened at ACHFF last week (0901-0905)?
Weekly Report · 09/08 10:37
Weekly Report: what happened at ACHFF last week (0825-0829)?
Weekly Report · 09/01 10:33
Arch Biopartners Inc. Reports Consistent Loss Per Share for Nine Months Ended June 30, 2025; Revenue Recognition Aligns with Period Agreements
Reuters · 08/30 01:46
Weekly Report: what happened at ACHFF last week (0818-0822)?
Weekly Report · 08/25 10:40
Weekly Report: what happened at ACHFF last week (0811-0815)?
Weekly Report · 08/18 10:35
Weekly Report: what happened at ACHFF last week (0804-0808)?
Weekly Report · 08/11 10:40
Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury
Barchart · 08/06 06:25
Weekly Report: what happened at ACHFF last week (0728-0801)?
Weekly Report · 08/04 10:42
Weekly Report: what happened at ACHFF last week (0721-0725)?
Weekly Report · 07/28 10:43
More
Webull provides a variety of real-time ACHFF stock news. You can receive the latest news about Arch Biopartners through multiple platforms. This information may help you make smarter investment decisions.
About ACHFF
Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute and chronic kidney diseases. The Company is advancing an integrated pipeline that includes new treatments targeting inflammation and toxin-induced kidney injury. Its programs include a pre-clinical chronic kidney disease platform targeting interleukin-32 (IL-32), LSALT peptide, a dipeptidase-1 (DPEP1) inhibitor in Phase II for preventing cardiac surgery-associated acute kidney injury, and cilastatin, a repurposed drug in Phase II for preventing toxin-induced kidney damage. These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting millions of patients worldwide. Its LSALT Peptide and cilastatin, are being developed to target kidney injury caused by inflammation or toxins respectively, which are both significant unmet medical needs.